9 completed. 9 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 9 |
| Phase 1 | 1 | Completed 1 |
Follow verinurad: new trials by email Literature Review of verinurad trials Research Report on verinurad
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Verinurad in Heart Failure With Preserved Ejection Fraction Verinurad, Allopurinol, Placebo for verinurad - Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 2 | Completed | AstraZeneca | 159 | 2020-05-19 | 2023-06-29 |
| A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia Verinurad, Allopurinol, Placebo for Verinurad - Chronic Kidney Disease | Phase 2 | Completed | AstraZeneca | 861 | 2019-07-23 | 2023-03-02 |
| A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA Verinurad, Febuxostat, Dapagliflozin - Asymptomatic Hyperuricemia | Phase 2 | Completed | AstraZeneca | 36 | 2017-10-25 | 2019-08-28 |
| Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria Verinurad 9 mg+Febuxostat 80 mg, Placebo - Hyperuricemia, Albuminuria | Phase 2 | Completed | AstraZeneca | 60 | 2017-05-18 | 2020-01-10 |
| Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects RDEA3170 2.5 mg, allopurinol 300 mg - Gout | Phase 2 | Completed | Ardea Biosciences, Inc. | 41 | 2015-07-28 | 2018-01-23 |
| A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients RDEA3170, Febuxostat, Benzbromarone - Gout and Asymptomatic Hyperuricemia | Phase 1 / Phase 2 | Completed | AstraZeneca | 110 | 2014-12-01 | 2015-06-12 |
| RDEA3170 and Febuxostat Combination Study in Gout Subjects RDEA3170 15 mg, RDEA3170 10 mg, RDEA3170 2.5 - Gout | Phase 2 | Completed | Ardea Biosciences, Inc. | 64 | 2014-10-01 | 2017-07-27 |
| Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia RDEA3170, Allopurinol, Placebo - Gout and Hyperuricemia | Phase 2 | Completed | AstraZeneca | 204 | 2014-01-05 | 2019-09-24 |
| RDEA3170 Monotherapy in Subjects With Gout Placebo, RDEA3170 5 mg, RDEA3170 10 mg - Gout | Phase 2 | Completed | Ardea Biosciences, Inc. | 172 | 2013-08-01 | 2015-07-01 |
Gout (6) · Hyperuricemia (3) · Albuminuria (1) · Diabetes Mellitus, Type 2 (1) · Heart Failure (1) · Renal Insufficiency, Chronic (1)
AstraZeneca (6) · Ardea Biosciences, Inc. (3)
United States (7) · Japan (2) · Mexico (2) · Poland (2) · Slovakia (2) · Argentina (1) · Australia (1) · Austria (1) · Bulgaria (1) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Israel (1)
Dalane Kitzman, MD (1) · J. Hall (1) · J. Hall, MD (1) · Jesse Hall, MD (1)
PMID 32951150, PMID 34383954, PMID 29531784, PMID 29657831, PMID 29868853, PMID 33075806, PMID 33130235, PMID 38564654, PMID 39141378
2019 (1)